哪些转移性癌症需要检测基因突变？首部二代测序指南来啦

参考文献：

[1] Mosele F, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. Ann Oncol, DOI:https:///10.1016/j.annonc.2020.07.014

[2] Marino P, Touzani R, Perrier L, et al. Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice:a nationwide French study. Eur J Hum Genet. 2018;26(3):314e323.

[3] Pagès A, Foulon S, Zou Z, et al. The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial.Genet Med. 2017;19(6):683e690

[4] Van Nimwegen KJM, van Soest RA, Veltman JA, et al. Is the $1000 genome as near as we think? A cost analysis of next-generation sequencing. Clin Chem. 2016;62(11):1458e1464

[5] J Mateo, D Chakravarty, R Dienstmann, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology. mdy263, https:///10.1093/annonc/mdy263